Cargando…
Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer
Introduction: Castration resistant prostate cancer (CRPC) has been characterized by a reactivation of the androgen receptor (AR) signaling pathway via alterations in androgen metabolism and AR aberrations. High-dose testosterone (HDT) is emerging as an active treatment in metastatic CRPC, however, b...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967778/ https://www.ncbi.nlm.nih.gov/pubmed/32002120 http://dx.doi.org/10.18632/oncotarget.27408 |
_version_ | 1783489012860715008 |
---|---|
author | Moses, Marcus Koksal, Ulkuhan Ledet, Elisa Manogue, Charlotte Cotogno, Patrick Lewis, Brian Layton, Jodi Sartor, A. Oliver Barata, Pedro |
author_facet | Moses, Marcus Koksal, Ulkuhan Ledet, Elisa Manogue, Charlotte Cotogno, Patrick Lewis, Brian Layton, Jodi Sartor, A. Oliver Barata, Pedro |
author_sort | Moses, Marcus |
collection | PubMed |
description | Introduction: Castration resistant prostate cancer (CRPC) has been characterized by a reactivation of the androgen receptor (AR) signaling pathway via alterations in androgen metabolism and AR aberrations. High-dose testosterone (HDT) is emerging as an active treatment in metastatic CRPC, however, biomarkers of response are unknown. We hypothesized that responses to HDT might impact the genomic expression of AR alterations found in circulating-tumor DNA (ctDNA). Methods: Retrospective analysis of mCRPC patients treated with HDT (testosterone cypionate q 2–4 weeks) with available clinical and somatic genomic data using a commercially available assay (Guardant360, Redwood City, CA). Clinical outcomes included PSA response (PSA50), time to PSA progression (TPP) and safety. Results: A total of 33 mCRPC patients were treated with ≥2 testosterone cypionate injections. ctDNA testing revealed alterations in AR (39%), TP53 (48%), and DNA repair genes (12%). HDT was given for median of 4.0 months (95% CI, 2.6–5.3) with 24% of PSA50. Twenty patients were re-challenged with abiraterone (n = 2) or enzalutamide (n = 18) with 30% PSA50. Significant (grade ≥3) adverse events were observed in 5% of patients (grade 4 thrombocytopenia and asthenia). Patients with median baseline ctDNA% of ≥1.10 had numerically worse TPP outcomes and all patients with AR alterations exhibited decreased AR expression post-HDT (n = 9), yet no association between clinical outcomes and ctDNA findings was observed. Conclusions: HDT led to a decrease in AR copy number and mutations which was independent from responses to therapy. Further understanding of the genomic alterations as potential predictor of response to HDT is needed. |
format | Online Article Text |
id | pubmed-6967778 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-69677782020-01-30 Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer Moses, Marcus Koksal, Ulkuhan Ledet, Elisa Manogue, Charlotte Cotogno, Patrick Lewis, Brian Layton, Jodi Sartor, A. Oliver Barata, Pedro Oncotarget Research Paper Introduction: Castration resistant prostate cancer (CRPC) has been characterized by a reactivation of the androgen receptor (AR) signaling pathway via alterations in androgen metabolism and AR aberrations. High-dose testosterone (HDT) is emerging as an active treatment in metastatic CRPC, however, biomarkers of response are unknown. We hypothesized that responses to HDT might impact the genomic expression of AR alterations found in circulating-tumor DNA (ctDNA). Methods: Retrospective analysis of mCRPC patients treated with HDT (testosterone cypionate q 2–4 weeks) with available clinical and somatic genomic data using a commercially available assay (Guardant360, Redwood City, CA). Clinical outcomes included PSA response (PSA50), time to PSA progression (TPP) and safety. Results: A total of 33 mCRPC patients were treated with ≥2 testosterone cypionate injections. ctDNA testing revealed alterations in AR (39%), TP53 (48%), and DNA repair genes (12%). HDT was given for median of 4.0 months (95% CI, 2.6–5.3) with 24% of PSA50. Twenty patients were re-challenged with abiraterone (n = 2) or enzalutamide (n = 18) with 30% PSA50. Significant (grade ≥3) adverse events were observed in 5% of patients (grade 4 thrombocytopenia and asthenia). Patients with median baseline ctDNA% of ≥1.10 had numerically worse TPP outcomes and all patients with AR alterations exhibited decreased AR expression post-HDT (n = 9), yet no association between clinical outcomes and ctDNA findings was observed. Conclusions: HDT led to a decrease in AR copy number and mutations which was independent from responses to therapy. Further understanding of the genomic alterations as potential predictor of response to HDT is needed. Impact Journals LLC 2020-01-07 /pmc/articles/PMC6967778/ /pubmed/32002120 http://dx.doi.org/10.18632/oncotarget.27408 Text en http://creativecommons.org/licenses/by/3.0/ Copyright: Moses et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Moses, Marcus Koksal, Ulkuhan Ledet, Elisa Manogue, Charlotte Cotogno, Patrick Lewis, Brian Layton, Jodi Sartor, A. Oliver Barata, Pedro Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer |
title | Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer |
title_full | Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer |
title_fullStr | Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer |
title_full_unstemmed | Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer |
title_short | Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer |
title_sort | evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967778/ https://www.ncbi.nlm.nih.gov/pubmed/32002120 http://dx.doi.org/10.18632/oncotarget.27408 |
work_keys_str_mv | AT mosesmarcus evaluationofthegenomicalterationsintheandrogenreceptorgeneduringtreatmentwithhighdosetestosteroneformetastaticcastrateresistantprostatecancer AT koksalulkuhan evaluationofthegenomicalterationsintheandrogenreceptorgeneduringtreatmentwithhighdosetestosteroneformetastaticcastrateresistantprostatecancer AT ledetelisa evaluationofthegenomicalterationsintheandrogenreceptorgeneduringtreatmentwithhighdosetestosteroneformetastaticcastrateresistantprostatecancer AT manoguecharlotte evaluationofthegenomicalterationsintheandrogenreceptorgeneduringtreatmentwithhighdosetestosteroneformetastaticcastrateresistantprostatecancer AT cotognopatrick evaluationofthegenomicalterationsintheandrogenreceptorgeneduringtreatmentwithhighdosetestosteroneformetastaticcastrateresistantprostatecancer AT lewisbrian evaluationofthegenomicalterationsintheandrogenreceptorgeneduringtreatmentwithhighdosetestosteroneformetastaticcastrateresistantprostatecancer AT laytonjodi evaluationofthegenomicalterationsintheandrogenreceptorgeneduringtreatmentwithhighdosetestosteroneformetastaticcastrateresistantprostatecancer AT sartoraoliver evaluationofthegenomicalterationsintheandrogenreceptorgeneduringtreatmentwithhighdosetestosteroneformetastaticcastrateresistantprostatecancer AT baratapedro evaluationofthegenomicalterationsintheandrogenreceptorgeneduringtreatmentwithhighdosetestosteroneformetastaticcastrateresistantprostatecancer |